Our Proprietary BEACON⁺ Platform

We have created our proprietary BEACON⁺ platform to unlock the biochemical roles of NAD⁺-utilizing enzymes and to discover and develop novel small molecule therapeutics. We have developed methods to identify and characterize the substrates of these enzymes and dissect the underlying biology. Through this process, we also identify biomarkers for use in patient selection and as early surrogates for clinical response. Our BEACON⁺ platform is designed to enable us to develop potent and selective small molecule modulators of NAD⁺-utilizing enzymes, including monoPARPs, and to efficiently assess their therapeutic potential through combinations of novel biological insights, molecular profiling, cell biology, in vivo models and genetic tools. The figure below depicts the components of our integrated BEACON⁺ platform.